Tandem Diabetes Care (NASDAQ:TNDM) Cut to “Neutral” at Citigroup

Citigroup lowered shares of Tandem Diabetes Care (NASDAQ:TNDM – Free Report) from a buy rating to a neutral rating in a report released on Tuesday, Marketbeat reports. Citigroup currently has $24.00 price target on the medical device company’s stock, down from their previous price target of $35.00. TNDM has been the subject of a number […]

Leave a Reply

Your email address will not be published.

Previous post Tevogen Bio (NASDAQ:TVGN) Research Coverage Started at D. Boral Capital
Next post Citigroup Forecasts Strong Price Appreciation for Warner Bros. Discovery (NASDAQ:WBD) Stock